Bavarian Nordic Rises Nearly 4% as Analysts See Strong RSV Vaccine Potential

2/9 09:21

  • (PLX AI) – Bavarian Nordic shares rose almost 4% in early trading after analysts upgraded their price targets on the stock, seeing strong potential for the company's RSV vaccine candidate.
  • • Bavarian's RSV human challenge readout is close to a best-case scenario with 79% efficacy, Danske said, lifting its price target to DKK 500 from DKK 420
  • • The efficacy demonstrated for MVA-BN RSV is robust and can be seen as comparable to the strong data from the JNJ and Pfizer human challenge trials: Danske
  • • Bavarian now has some of the best RSV vaccine challenge data available, significantly de-risking the project, Nordea said, raising its price target to DKK 432 from DKK 411
  • • Bavarian is now likely to accelerate partner discussions for the vaccine, and a license deal could happen during the first half of next year: Nordea
  • • Both Nordea and Danske rate Bavarian Nordic buy